Drug Profile

AMFX 200

Alternative Names: AMFX-200

Latest Information Update: 30 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amphix Bio
Class Peptides
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Spinal cord injuries
New Molecular Entity Yes

Highest Development Phases

Preclinical Spinal cord injuries

Most Recent Events

21 Jul 2025 Amphix Bio has patent protection for Supramolecular Therapeutic Peptide (STP) Platform, prior to July 2025 (Amphix Bio website, July 2025)
16 Jul 2025 Amphix Bio plans a first-in-human clinical trials for Spinal cord injuries
16 Jul 2025 Preclinical trials in Spinal cord injuries in USA (Intrathecal), prior to July 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com